Here we report the results of autologous and allogenic SCT in a single institution in Bogotá, Colombia, between 1993 and 2007. We performed 532 SCT in 526 patients, 227 allogenic and 305 autologous. In 294 (96.4%) of autologous-SCT, stem cells were obtained from peripheral blood. Mean 2.97 × 106/kg (0.31–30) CD34+ cells, in 3 (1–8) apheresis, were collected. 224 (73.7%) were movilized using Cyclofosfamide plus G-SCF. The rest were movilized with various chemotherapy regimens or G-CSF alone. Indications for auto-SCT were: Non-Hodgkins Lymphoma 115, Hodgkin disease 93, multiple myeloma 59, solid tumors 18, acute leukemias 17, other 3. Mean age was 40.1 years (5–68). 189 (61.9%) were male. Most common conditioning regimens for lymphomas were BEAM and BEM. All MM patients were conditioned with Melphalan 200 mg/m2. Hospitalization median time was 27 days (14–87). Day 100 TRM (transplant related mortality) was 6.23%. At mean 31.23 months (0.16–161) follow up overall and relapse free survival are 71% and 66.4% respectively. 60% of deaths were related to disease relapse. Of 227 allo-SCT, in 214 SC were obtained from peripheral blood, only 13 were obtained from bone marrow. 153 (59%) were males. Most common indications for transplant were: Chronic myeloid leukemia 57, acute myeloid leukemia 46, acute lymphoid leukemia 41, bone marrow failure syndromes 44, Hodgkin's and non-Hodgkin lymphomas 14, MDS 9, other 12. Mean age was 30.1 (4–63) years. 72% of patients and 76% of donors were IgG CMV positive. Most common conditioning regimens for acute leukemias and lymphomas were BuCy, BuCy-etoposide, busulfan-fludarabine; and for aplastic anemia high dose cyclofosfamide or cyclophosphamide plus ATG. Hospitalization median time was 34 days (17–103). Day 100 TRM was 16.7%. At mean 25.72 months (0.27–147) follow up, overall and relapse free survival are 53.2% and 50.9% respectively. Results described here are similar of ones reported in other centers around de world, they confirm that SCT is feasible in centers of developing world.